Literature DB >> 12495359

Patients' understanding of risk associated with medication use: impact of European Commission guidelines and other risk scales.

Dianne C Berry1, D K Raynor, Peter Knapp, Elisabetta Bersellini.   

Abstract

Patients want and need comprehensive and accurate information about their medicines so that they can participate in decisions about their healthcare. In particular, they require information about the likely risks and benefits that are associated with the different treatment options. However, to provide this information in a form that people can readily understand and use is a considerable challenge to healthcare professionals. One recent attempt to standardise the language of risk has been to produce sets of verbal descriptors that correspond to specific probability ranges, such as those outlined in the European Commission (EC) Pharmaceutical Committee guidelines in 1998 for describing the incidence of adverse effects. This paper provides an overview of a number of studies involving members of the general public, patients, and hospital doctors, that evaluated the utility of the EC guideline descriptors (very common, common, uncommon, rare, very rare). In all studies it was found that people significantly over-estimated the likelihood of adverse effects occurring, given specific verbal descriptors. This in turn resulted in significantly higher ratings of their perceived risks to health and significantly lower ratings of their likelihood of taking the medicine. Such problems of interpretation are not restricted to the EC guideline descriptors. Similar levels of misinterpretation have also been demonstrated with two other recently advocated risk scales (Calman's verbal descriptor scale and Barclay, Costigan and Davies' lottery scale). In conclusion, the challenge for risk communicators and for future research will be to produce a language of risk that is sufficiently flexible to take into account different perspectives, as well as changing circumstances and contexts of illness and its treatments. In the meantime, we urge the EC and other legislative bodies to stop recommending the use of specific verbal labels or phrases until there is a stronger evidence base to support their use.

Entities:  

Mesh:

Year:  2003        PMID: 12495359     DOI: 10.2165/00002018-200326010-00001

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  19 in total

Review 1.  Compliance with prescribed drugs: challenges for the elderly population.

Authors:  S Claesson; A Morrison; A I Wertheimer; M L Berger
Journal:  Pharm World Sci       Date:  1999-12

Review 2.  The visual communication of risk.

Authors:  I M Lipkus; J G Hollands
Journal:  J Natl Cancer Inst Monogr       Date:  1999

3.  Risks--listen and don't mislead.

Authors:  A Edwards; G J Elwyn
Journal:  Br J Gen Pract       Date:  2001-04       Impact factor: 5.386

Review 4.  Explaining risks: turning numerical data into meaningful pictures.

Authors:  Adrian Edwards; Glyn Elwyn; Al Mulley
Journal:  BMJ       Date:  2002-04-06

5.  Communicating risk reductions. Researchers should present results with both relative and absolute risks.

Authors:  A Edwards; G Elwyn; N Stott
Journal:  BMJ       Date:  1999-02-27

Review 6.  Cancer: science and society and the communication of risk.

Authors:  K C Calman
Journal:  BMJ       Date:  1996-09-28

7.  Concepts in risk-benefit assessment. A simple merit analysis of a medicine?

Authors:  R Edwards; B E Wiholm; C Martinez
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

8.  Communicating risk. Use of standard terms is unlikely to result in standard communication.

Authors:  A Edwards; R Pill; N Stott
Journal:  BMJ       Date:  1996-12-07

9.  Patients' interpretations of verbal expressions of probability: implications for securing informed consent to medical interventions.

Authors:  D J Mazur; J F Merz
Journal:  Behav Sci Law       Date:  1994

10.  Provision of information about drug side-effects to patients.

Authors:  D C Berry; P Knapp; D K Raynor
Journal:  Lancet       Date:  2002-03-09       Impact factor: 79.321

View more
  28 in total

1.  Strategies to help patients understand risks.

Authors:  John Paling
Journal:  BMJ       Date:  2003-09-27

Review 2.  Pharmacovigilance of herbal medicines : a UK perspective.

Authors:  Joanne Barnes
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

3.  Barriers to contraceptive use in product labeling and practice guidelines.

Authors:  Daniel Grossman; Charlotte Ellertson; Katrina Abuabara; Kelly Blanchard; Francisco T Rivas
Journal:  Am J Public Health       Date:  2006-01-31       Impact factor: 9.308

4.  What is drug safety?: celebrating 20 years of the Drug Safety journal.

Authors:  I Ralph Edwards
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

5.  Comprehension of the description of side effects in drug information leaflets: a survey of doctors, pharmacists and lawyers.

Authors:  Andreas Ziegler; Anka Hadlak; Steffi Mehlbeer; Inke R König
Journal:  Dtsch Arztebl Int       Date:  2013-10-04       Impact factor: 5.594

6.  Effect of Communication Style on Perceptions of Medication Side Effect Risk among Pharmacy Students.

Authors:  Ruta V Sawant; Collin R Beatty; Sujit S Sansgiry
Journal:  Am J Pharm Educ       Date:  2016-10-25       Impact factor: 2.047

7.  Adverse drug reactions: when the risk becomes a reality for patients.

Authors:  Anthony R Cox; Tehreem F Butt
Journal:  Drug Saf       Date:  2012-11-01       Impact factor: 5.606

8.  'I'll do what they did": social norm information and cancer treatment decisions.

Authors:  Brian J Zikmund-Fisher; Paul D Windschitl; Nicole Exe; Peter A Ubel
Journal:  Patient Educ Couns       Date:  2011-03-01

9.  Comparison of two methods of presenting risk information to patients about the side effects of medicines.

Authors:  P Knapp; D K Raynor; D C Berry
Journal:  Qual Saf Health Care       Date:  2004-06

Review 10.  Over-the-counter analgesics in older adults: a call for improved labelling and consumer education.

Authors:  Christianne L Roumie; Marie R Griffin
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.